Table 2.
Comparison of Hazard Ratio (95% CI) and Relative Time (95% CI) to Composite Event of End-Stage Kidney Disease or >50% Decline in GFR Across Two Different Analytic/Design Strategies and Two Different suPAR Assays
| Lognormal Survival Analysisa | Study A (ELISA) |
Study B (MSD) |
||||||
|---|---|---|---|---|---|---|---|---|
| Model 1: Fully Adjusted Without eGFRb |
Model 2: Fully Adjusted With eGFRc |
Model 1: Fully Adjusted Without eGFRb |
Model 2: Fully Adjusted With eGFRc |
|||||
| RT (95% CI) | P | RT (95% CI) | P | RT (95% CI) | P | RT (95% CI) | P | |
| SuPAR quartiles | ||||||||
| 1 | 1 | Ref | 1 | Ref | 1 | Ref | 1 | Ref |
| 2 (vs 1) | 0.67 (0.50-0.89) | 0.006 | 0.76 (0.57-1.02) | 0.07 | 0.99 (0.75-1.31) | 0.94 | 1.18 (0.89-1.58) | 0.25 |
| 3 (vs 1) | 0.56 (0.42-0.74) | <.001 | 0.72 (0.54-0.96) | 0.02 | 0.57 (0.44-0.75) | <.001 | 0.82 (0.62-1.11) | 0.19 |
| 4 (vs 1) | 0.44 (0.33-0.58) | <.001 | 0.65 (0.48-0.87) | 0.004 | 0.54 (0.41-0.70) | <.001 | 0.90 (0.66-1.22) | 0.49 |
| Type III testd | <.001 | 0.04 | <.001 | 0.089 | ||||
| Cox Regression Analysise | Model 1: Fully Adjusted Without eGFRf |
Model 2: Fully Adjusted With eGFRg |
Model 1: Fully Adjusted Without eGFRf |
Model 2: Fully Adjusted With eGFRg |
||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| SuPAR quartiles | ||||||||
| 1 | 1 | Ref | 1 | Ref | 1 | Ref | 1 | Ref |
| 2 (vs 1) | 1.87 (1.13-3.09) | 0.02 | 1.44 (0.87-2.39) | 0.16 | 1.23 (0.72-2.10) | 0.46 | 0.85 (0.50-1.47) | 0.56 |
| 3 (vs 1) | 2.69 (1.64-4.41) | <.001 | 1.71 (1.03-2.84) | 0.04 | 2.33 (1.42-3.84) | <.001 | 1.04 (0.61-1.77) | 0.90 |
| 4 (vs 1) | 3.36 (2.07-5.46) | <.001 | 1.74 (1.03-2.95) | 0.04 | 3.00 (1.83-4.91) | <.001 | 1.05 (0.60-1.84) | 0.87 |
| Type III testd | <.001 | 0.17 | <.001 | 0.82 | ||||
Differences in the number of composite events arise from different administrative censoring times in the 2 studies.
Abbreviations: BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; ELISA, enzyme-linked immunosorbent assay (Quantikine); HR, hazard ratio; MSD, Meso Scale Discovery; Ref, reference; RT, relative time; suPAR, soluble urokinase plasminogen activator receptor; UPCR, urinary protein-creatinine ratio.
For lognormal models, n = 518, events = 170.
Model 1: Adjusted for age, gender, race, ethnicity, hypertension (systolic BP percentiles), antihypertensive use, BMI, UPCR category, glomerular diagnosis; n = 23 were omitted due to missing.
Model 2: Model 1 plus eGFR; n = 23 were omitted due to missing.
Type III tests the overall effect of suPAR across all levels of suPAR.
For Cox models, n = 541, events = 184.
Model 1: Adjusted for age, gender, hypertension (systolic/diastolic BP percentiles), BMI z score, glomerular diagnosis, log base 2 UPCR.
Model 2: Model 1 plus eGFR.